手机版|
二维码|
邮编：201203
联系人：杨经理
电话：021-50724187 021-50724961
传真：021-50724961
手机：15921799099
留言：发送留言
个性化：www.qfbio.com
网址：www.qfbio.com
商铺： 文件下载 图片下载
产品名称：英夫利昔（inlfiximab）抗体ELISA试剂盒型 号：TR-Q-INFLIXIv2所属分类：土耳其matriks试剂盒价格：12000包装：96t生产地：土耳其
样本量( l)10总时间 (min)70测试样本Serum, plasma包装规格（T）96灵敏度 (ng/mL)30回收率 (%)97有效期 (年)1
Infliximab，注册商标为Remicade，中文名字为英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克。
英夫利昔单抗（Infliximab，Remicade）是一类相对新型的生物制剂。为高亲和性结合肿瘤坏死因子alpha (TNF- )的嵌合体单抗，其被广泛应用于治疗自身免疫性疾病。因此，检测英夫利昔单抗、抗英夫利昔抗体血药浓度及水平在治疗和个性化用药上具有重要意义。
Matriks Biotechnology专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内浓度或因用该抗体药产生的抗体的体内浓度。Matriks Biotek , SHIKARI 和KLONART 为Matriks Biotechnology注册的产品商标。其产品达到ISO 13485 CE IVD标准。
英夫利昔(Infliximab， Remicade ) ELISA (Specific) 试剂盒
英文名称：SHIKARI QS-INFLIXI ELISA KIT； 货号：TR-QS-INFLIXlv1； 规格：96T
英文描述：Enzyme immunoassay for the quantitative determination of Infliximab (Remicade ) in serum and plasma and other biological fluids
中文描述：ELISA方法特异性定量测定血清、血浆或其他生物液体中的英夫利昔单抗(Infliximab， Remicade )的浓度
SHIKARI Q-INFLIXI ELISA KIT使用单克隆抗体高专一性结合血清、血浆或其他生物液中的英夫利昔单抗(Infliximab， Remicade )，是当前*一款用于定量检测英夫利昔(Infliximab， Remicade )体内浓度的特异性ELISA试剂盒。
引用文献：# PEER REVIEWED JOURNAL ARTICLES:1 Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF- Drugs Differently Affect the TNF -sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.**4 Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.**6 Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn s and Colitis Advance Access published April 21, 2016.7 Guti rrez A, Zapater P, Juanola O, Sempere L, Garc a M, Laveda R, Mart nez A, Scharl M, Gonz lez-Navajas JM, Such J, Wiest R, Rogler G, Franc s R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn s Disease. Am J Gastroenterol. Apr;111(4):529-40, 2016.8 Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116 122, 2016.**9 Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2016) 3:155 166 **10 Bortlik M., et al., Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology, 2016 vol. 51, no. 2, 196 202.11 Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov. 2015), PP 95-100.**14 Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn s disease. J Gastroenterol (2015) 50:758 768.16 Mal ckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015.17 Farkas K. et al, Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn s disease and ulcerative colitis experiences from a single center. Expert Opin. Biol. Ther. 15:(9) 2015.18 Lee Y.M. et al, Infliximab Top-Down Strategy is Superior to Step-Up in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPGN 60: (737 743), 2015.19 Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015.**22 Pallagi-Kunst r . et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. **23 Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology Hepatology, August (478-489),2014. **24 Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology Hepatology 26:(485-487), 2014.27 Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.29 Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn s disease, Gut 0:1 9, 2013. **30 Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. **33 Bortlik M et al, Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study , Scandinavian Journal of Gastroenterology. 48: 951 958, 201334 Bortlik M, et al, Infliximab trough levelsmay predict sustained response to infliximab in patients with Crohn s disease, Journal of Crohn s and Colitis 2012. **35 Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. **36 Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **37 Seok Lee Y, et al, Efficacy of Early Infliximab Treatment for Pediatric Crohn s Disease: A Three-year Follow-up , Pediatric Gastroenterology, Hepatology Nutrition 2012; 15(4):243-249 **38 Molnar T, et al, Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease , Z Gastroenterol 2012; 50 - A5339 Kato S, et al, Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn s Disease Patient , Crohn s Colitis Foundation of America 201140 Adisen E, et al, Anti-infliximab antibody status and its relation to clinical response in psoriatic patients : A pilot study, Journal of Dermatology 2010; 37: 708 713.
Matriks Biotechnology 抗体药的药效及个体化应用专家
抗体药是一类相对新型的生物制剂。检测抗体药及其抗体水平在治疗和个性化用药上具有重要意义。大量的临床和制药公司都在致力于抗体药物的浓度水平和疗效的研究。Matriks生物技术公司专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内含量或因用于产生的针对相应抗体药的抗体的体内含量。Matriks Biotek?, SHIKARI?和KLONART?为Matriks生物技术公司注册的产品商标。其产品达到ISO 13485 CE IVD标准。
Matriks生产用于检测抗体药在体内的浓度和疗效的试剂盒主要针对如下几种抗体药。
1. Infliximab注册商标为Remicade，由Schering-Plough生产，中文名字为英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克。
Infliximab为高亲和性结合肿瘤坏死因子alpha (TNF- )的嵌合体单抗，其被广泛应用于治疗自身免疫性疾病。Matriks Biotek Shikari Infliximab ELISA使用单克隆抗体高专一性结合血清、血浆和其他生物液中的Infliximab，是当前*的一款用于定量检测Infliximab (Remicade?)体内含量的特异性ELISA试剂盒。
2. Adalimumab注释商标为Humira, 为Abbott Laboratories产品，中文名阿达木单抗、修美乐。
Adalimumab为特异性结合TNF- 的人源性抗体，Adalimumab通过阻止TNF- 与其细胞表面受体相结合，发挥抗炎作用。
Matriks Biotek shikari抗体检测抗Adalimumab抗体，用于检测治疗过程中抗Adalimumab抗体状况，为医师提供时机以减少抗Adalimumab抗体产生（例如添加免疫抑制性药物），以阻止抗体药失效。
3. Etanercept商标为Enbrel和Altebrel，中文名依那西普，恩利.
是一种干扰TNF- 、用于自身免疫性疾病治疗的生物药物。针对Etanercept的特异性单抗用于检测血样中Etanercept量。Matriks Biotek Shikari Q-ETA是市面上首款用于定量检测Etanercept的ELISA试剂盒。
4. 人肿瘤坏死因子及受体
Matriks Biotek开发的高敏感度、专一性TNF- 检测试剂盒，该试剂盒基于固定在固相面上的针对TNF-alpha的单抗和标记了马辣根过氧化物酶的另一单抗经三明治夹心法检测TNF- 。
5. Bevacizumab商标名为Avastin?，由Genentech/Roche生产，中文名为阿瓦斯汀、贝伐单抗、安维汀、癌思停。
Bevacizumab为血管生成抑制剂，在包括结肠和直肠癌、肺癌、乳腺癌、肾癌、卵巢癌等多种肿瘤中被批准使用。Matriks Biotek Shikari Q-BEVA Enzyme Immunoassay用于检测血清或血浆中游离bevacizumab含量。以便保证其有效的血药浓度。
6. Rituximab商标为Rituxan, Mabthera, Zytux，中文名为利妥昔单抗注射剂、美罗华、利妥昔单抗、利克散、贺普丁、莫須瘤。
Rituximab为针对B细胞表面抗原CD20蛋白的嵌合型单克隆抗体。Rituximab可破坏B细胞，从而用于治疗包括多种白血病、淋巴瘤、移植排斥和自身免疫失调性疾病等多种因B细胞过量、B细胞高反应性和B细胞功能失调引起的疾病。Rituximab的使用可引起机体产生相应抗体。Matriks Biotek Rituximab-ELISA和Rituximab抗体分别用于测定机体内rituximab及其抗体的水平，从而为维持有效rituximab的血药浓度和提供抗抗体措施提供预防性举措。
7. Trastuzumab商标名为Herclon, Herceptin，中文名为赫赛汀、賀癌平、曲妥珠单抗。
Trastuzumab为干扰HER2/neu受体的单克隆抗体，其主要用于乳腺癌的治疗。Trastuzumab的使用可导致机体产生抗Trastuzumab抗体。Matriks Biotek Trastuzumab-ELISA和抗体分别用于检测机体trastuzumab和其抗体的浓度。
Matriks Biotek抗体药个性化用药测试盒产品目录
中文名称
英文名称
货号
规格
Infliximab，商标Remicade，英利昔单抗、英夫利昔、因福利美、瑞米凯德、类克
英夫利昔单抗（类克）ELISA试剂盒
SHIKARI QS-INFLIXI ELISA KIT
TR-QS-INFLIXIv1
96T
英夫利昔单抗（类克）ELISA试剂盒
SHIKARI Q-INFLIXI ELISA KIT
TR-Q-INFLIXIv2
96T
抗英夫利昔单抗（类克）抗体ELISA试剂盒
SHIKARI Q-ATI ELISA KIT
TR-ATIv4
96T
Adalimumab，商标Humira，阿达木单抗、修美乐
阿达木单抗（修美乐）ELISA试剂盒
SHIKARI Q-ADA ELISA KIT
TR-ADAv1
96T
抗阿达木单抗（修美乐）抗体ELISA试剂盒
SHIKARI S-ATA ELISA KIT
TR-A-ADAv1
96T
Etanercept，商标Enbrel、Altebrel，依那西普、恩利
依那西普（恩利）ELISA试剂盒
SHIKARI Q-ETA ELISA KIT
TR-ETAv1
96T
抗依那西普（恩利）抗体ELISA试剂盒
SHIKARI S-ATE ELISA KIT
TR-AETAv2
96T
人肿瘤坏死因子及受体
TNF- ELISA试剂盒
SHIKARI Q-TNF ELISA KIT
TR-TNFv1
96T
TNF-RII（p75/80 kDa）ELISA试剂盒
SHIKARI Q-sTNF-RII ELISA KIT
TR-sTNF-RIIv1
96T
Bevacizumab，商标Avastin，阿瓦斯汀、贝伐单抗、安维汀、癌思停
贝伐单抗（安维汀）ELISA试剂盒
SHIKARI Q-BEVA ELISA KIT
TR-BEVAv1
96T
抗贝伐单抗（安维汀）抗体ELISA试剂盒
SHIKARI S-ATB ELISA KIT
TR-ABEVAv1
96T
Rituximab，商标Rituxan、Mabthera，利妥昔单抗、美罗华、利克散、贺普丁、莫須瘤
利妥昔单抗（美罗华）ELISA试剂盒
SHIKARI Q-RITUX ELISA KIT
TR-RTXv1
96T
抗利妥昔单抗（美罗华）抗体ELISA试剂盒
SHIKARI S-ATR ELISA KIT
TR-ARTXv1
96T
Trastuzumab，商标Herclon,、Herceptin，曲妥珠单抗、赫赛汀、賀癌平
曲妥珠单抗（赫赛汀）ELISA试剂盒
SHIKARI Q-TRAS ELISA KIT
TR-TRASv1
96T
抗曲妥珠单抗（赫赛汀）抗体ELISA试剂盒
SHIKARI S-ATT ELISA KIT
TR-ATRASv1
96T
我们公司zui大优势是强大的采购，
1：基本什么都能进口，血清，抗体，耗材，还有部分限制进口的，
2：货品全，现经营过700多个品牌，基本所有生物试剂耗材都可以进口，特别是冷偏的产品那就更有优势，
3：提供加急服务，一般1-2周到货，超过时限加急费全免
4：价格公道，绝大部分价格有优势，当然不能保证100%产品都是价格zui低,因为价格zui低意味着没有服务.
5：良好的信誉，大部分客户我们提供货到付款服务，客户包括清华，北大 交大 复旦，中山等100多所大学，ROCHE，阿斯利康，国药 ，fisher等500多家公司
6：我们还是Santa,Advanced Biotechnologies Inc, Sorachim ,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. Dako,Inc, GePromegaridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,Sorachim , Polysciences,prospecbi, QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等几十家国外公司授权代理。
7：我们还是invitrogen,qiagen,Sorachim am,sigma;Promega,roche,merck, rnd,BD, GE,pierce,BioLegend等知名大品牌批发，欢迎合作。
上海起发实验试剂有限公司
：杨建辉
400：
办公：
*8006
企业:
:。。ｃｏｍ/
地址：上海市浦东新区晨阳路225弄东方现代商业广场46号303室(近东亭路)
[ 打印 ] [ 返回顶部 ] [ 关闭 ]
